Bibliography For Survodutide

Every Curated Peer-Reviewed Reference Indexed For This Compound. Each Citation Can Be Exported In BibTeX, RIS, EndNote, Or Plain Text.

Indexed Types:study

n.d. - study

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.

Unknown Authors.

n.d. - study

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.

Unknown Authors.

n.d. - study

Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.

Unknown Authors.

n.d. - study

Future Directions in the Medical Treatment of Obesity: A Narrative Review.

Unknown Authors.

n.d. - study

Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.

Unknown Authors.

n.d. - study

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

Unknown Authors.

n.d. - study

Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.

Unknown Authors.

n.d. - study

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.

Unknown Authors.

n.d. - study

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.

Unknown Authors.

n.d. - study

Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis.

Unknown Authors.

n.d. - study

Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.

Unknown Authors.

n.d. - study

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.

Unknown Authors.

n.d. - study

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence.

Unknown Authors.

n.d. - study

Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.

Unknown Authors.

n.d. - study

Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH).

Unknown Authors.

n.d. - study

Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit With GLP-1/Glucagon Agonism.

Unknown Authors.

n.d. - study

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

Unknown Authors.

n.d. - study

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.

Unknown Authors.

n.d. - study

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

Unknown Authors.

n.d. - study

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

Unknown Authors.

n.d. - study

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.

Unknown Authors.

n.d. - study

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Unknown Authors.

n.d. - study

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Unknown Authors.

n.d. - study

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.

Unknown Authors.

n.d. - study

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.

Unknown Authors.

n.d. - study

Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.

Unknown Authors.

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.

Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.

Future Directions in the Medical Treatment of Obesity: A Narrative Review.

Review: Special Issue: &lt;i&gt;Real-world evidence on the use of GLP1 receptor agonists&lt;/i&gt;: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.

Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.

Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis.

Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence.

Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.

Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH).

Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit With GLP-1/Glucagon Agonism.

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m&lt;sup&gt;2&lt;/sup&gt; in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.

Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.

Review: Special Issue: <i>Real-world evidence on the use of GLP1 receptor agonists</i>: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.